Method for producing a composition for promoting survival of transplanted hematopoietic stem cell
US8394368B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 10, 2011 |
| Grant date | Mar 12, 2013 |
| Priority date | — |
| Expiry date | Jan 10, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
HLA matched activated lymphocytes in mononuclear cells separated from peripheral blood or umbilical cord blood are proliferated and activated. After separating and collecting, the HLA matched activated lymphocytes are employed as the main component of a composition for promoting survival of transplanted hematopoietic stem cells. The obtained composition is widely usable in, for instance, prevention of survival failure of transplanted hematopoietic stem cells and therapy for promoting the survival thereof. Although the dose of the composition varies depending on the age, conditions, etc. of a patient, a humanized antibody is administered in a dose of from 0.2 to 20 ml/kg/day to mammals including humans. The composition is administered by intravenous injection either once a day (single administration or continuous administration) or intermittently once to 3 times in a week or once in 2 or 3 weeks.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.